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Abstract Methylphenidate (MPH) is the most commonly
prescribed stimulant for children with ADHD. Data on the
effects of different MPH formulations in real-life settings
are scarce, and the role of previous therapy on treatment
outcome when switching medications has not been well
studied. OBSEER was an observational study designed to
evaluate the effectiveness and safety of Equasym XL
 in
routine care. This study assessed whether the improve-
ments reported with Equasym XL
 are inﬂuenced by the
degree of symptom control achieved with the previous
medication. Patients enrolled in OBSEER were stratiﬁed
by prior treatment (none, MPH-immediate release [IR]
once daily [o.d.] [MPH-IR o.d.], MPH-IR repeated [MPH-
IR [o.d.] and MPH-MR [modiﬁed release] excluding
Equasym XL
), and changes in ADHD and other exter-
nalising symptoms (CGI-S, FBB-ADHD and DAYAS) and
quality of life (QoL, KINDL) were evaluated during
treatment with Equasym XL
. A total of 782 patients were
analysed. Signiﬁcant group-by-time interactions were
found for all symptom variables analysed, indicating that
effects varied by previous medication. For CGI-S and
FBB-ADHD total scores, the greatest reductions in ADHD
symptoms were observed in the treatment-naı ¨ve subgroup,
followed (in order) by MPH-IR o.d., MPH-IR [o.d. and
MPH-MR. A similar proﬁle was seen for DAYAS ratings
for all periods of the day except the evening, when there
were no signiﬁcant differences between subgroups. Simi-
larly, the treatment-naı ¨ve and MPH-IR o.d. subgroups
showed the greatest improvements in KINDL ratings.
Although effects were greatest for treatment-naı ¨ve patients,
improvements were also observed in the prior treatment
subgroups for symptoms and QoL. This suggests that a
change to Equasym XL
 may be beneﬁcial in patients with
suboptimal effects on prior medication.
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Introduction
The use of stimulants for the treatment of attention deﬁcit
hyperactivity disorder (ADHD) in children and adolescents
is known to provide signiﬁcant short-term improvements
both in the core symptoms of the disease (inattention,
hyperactivity and impulsivity) and in the behavioural
problems associated with it (e.g. aggressive behaviour,
depressive mood, anxiety, tics, impaired social functioning
and academic productivity) [22].
Methylphenidate (MPH) is the most commonly pre-
scribed stimulant for children with ADHD. It is charac-
terised by a short half-life of 2–3 h and reaches its
maximum effect 1.5–2 h after dosing [21]; therefore,
immediate-release (IR) MPH formulations require repeated
administration during the day in order to maintain effec-
tiveness, and 2–3 daily doses are normally needed for most
children [15]. As multiple dosing can cause adherence
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DOI 10.1007/s00787-011-0205-1issues and problems in terms of privacy, stigmatisation by
classmates and potential abuse [13], several long-acting
MPH formulations have been developed in the past few
years that combine IR and modiﬁed-release (MR) compo-
nents, allowing rapid onset of therapeutic effect and suf-
ﬁcient duration to eliminate the need for additional doses.
All available long-acting preparations provide a mixture of
MPH-IR and -MR, but differ in the type of modiﬁed
delivery system used and in the proportion of IR-to-MR
components [3], which results in distinct pharmacokinetic
proﬁles over time; this is reﬂected by patterns of efﬁcacy
and action on behaviour throughout the day that are spe-
ciﬁc for each long-acting MPH formulation [3, 22]. Equ-
asym XL
1 (Shire Pharmaceuticals Ireland Limited,
Ireland) combines 30% MPH-IR and 70% MPH-MR,
producing a fast initial increase in MPH plasma concen-
tration followed by a second increase approximately 3 h
later and maintaining therapeutic concentration for about
8h[ 20, 24]; it has been shown to be as effective as MPH-
IR given twice daily [12].
Although different MPH preparations have been com-
pared directly in randomised clinical trials—such as the
COMACS study [22] or the above-mentioned study com-
paring Equasym XL
 and MPH-IR [12]—empirical data
on the effects of different MPH formulations in a natural,
real-life setting are scarce. Results from a European open-
label study investigating the effectiveness and tolerability
of a long-acting MPH formulation (osmotic release oral
system [OROS] MPH [Concerta
, Janssen-Cilag Ltd, UK])
in children and adolescents treated previously with MPH-
IR revealed that symptom control was maintained or
improved after switching to the long-acting formulation;
the improvement was more evident to parents than teach-
ers, possibly reﬂecting increased symptom control in the
second part of the day after school [17]. Another open-label
study analysed the effect of abrupt conversion from a stable
dose of oral MPH-MR to an MPH transdermal system
(Daytrana
, Noven Therapeutics LLC, Miami, USA)
showing that the transdermal system may further improve
ADHD symptoms and quality of life (QoL) when titrated
carefully [2, 6]. However, none of these studies considers
different previous therapies and speciﬁcally compares their
inﬂuence on treatment outcome when patients are switched
to a different medication.
In another observational study, Do ¨pfner et al. examined
the effectiveness and tolerability of an MPH-MR
preparation with a 50% IR component (Medikinet
 Retard/
XL, Medice, Germany) in 447 patients aged 6–17 years
with ADHD, and with an indication for treatment with this
preparation [9]. ADHD symptom severity declined signif-
icantly. Oppositional behaviour and side effects as rated by
parents were also reduced. The authors found the strongest
effects in treatment-naı ¨ve children, and somewhat weaker
effects in children who had received previous treatment
with an alternative MPH on the different outcome mea-
sures tested.
The OBSEER (OBservation of Safety and Effectiveness
of Equasym XL
 in Routine care) study [8, 19] was a non-
interventional, post-marketing surveillance study con-
ducted in Germany to evaluate the effectiveness and safety
of Equasym XL
 under routine care conditions. It included
children diagnosed with ADHD or hyperkinetic disorder
(HKD) either previously untreated or treated with different
formulations of MPH, who started treatment with, or were
switched to, Equasym XL
.
To test the hypothesis that the extent of improvement
reported with Equasym XL
 is inﬂuenced by the degree of
symptom control achieved with a previous medication,
patients enrolled in the OBSEER study were stratiﬁed
according to prior treatment, and changes in ADHD
symptoms, other externalising symptoms and QoL were
evaluated during treatment with Equasym XL
.
Methods
Participants and study design
OBSEER was a post-marketing observational study of
Equasym XL
, designed primarily to assess effectiveness
and safety in clinical practice and conducted in 169 centres
in Germany in accordance with local regulations and under
the therapeutic responsibility of the attending physicians;
ethics or institutional review board approval was not
required for this study. Written informed consent was
obtained from parents. The study included children aged
6–17 years with a conﬁrmed diagnosis of ADHD according
to the Diagnostic and Statistical Manual of the American
Psychiatric Association (DSM-IV-TR) [1] or HKD
according to the International Classiﬁcation of Diseases
(ICD-10) [25], for whom therapy with Equasym XL
 was
already planned by the treating physician. Details regarding
study design and participants are described elsewhere in
this supplement [8]. For this analysis, patients enrolled in
the OBSEER study were stratiﬁed by pharmacological
treatment received prior to study initiation. Four subgroups
were considered: treatment-naı ¨ve, MPH-IR once daily
(o.d.; MPH-IR o.d.), MPH-IR more than o.d. (MPH-IR
[o.d.) and MPH-MR other than Equasym XL
. Children
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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123who had previously been administered drugs other than
MPH or for whom prior treatment was not speciﬁed were
not included in the analysis.
Outcome measures
Measures of ADHD symptoms and QoL in the OBSEER
study were obtained using the following tools.
1. German ADHD symptom checklist (Fremdbeurteilungs-
bogen fu ¨r Aufmerksamkeitsdeﬁzit-Hyperaktivita ¨tssto ¨-
rung, FBB-ADHD) [5, 10, 11]. FBB-ADHD is part of
the German diagnostic system for mental disorders in
children and adolescents (DISYPS-II) [10] and assesses
20 symptom items, which are rated by teachers and
parents on a scale ranging from 0 = not at all, to
3 = very much, with higher scores indicating more
severe symptoms. Nine symptom items are combined
into a subscale assessing inattention, and 11 items are
combined to assess hyperactivity and impulsivity; the
total symptom score covers all 20 symptom items. In
addition, four items evaluate functional impairment with
respect to school performance, relationship towards
adults and children, and the subjective level of suffering
(functional impairment subscale), and six items assess
competences regarding attentive, reﬂexive and enduring
behaviour (attention–reﬂexivity subscale).
2. ADHD-Clinical Global Impression–Severity (ADHD-
CGI-S). A scale assessing ADHD core symptoms
(inattention, hyperactivity and impulsivity) and disease-
associated problems (aggressive behaviour, depressive
mood, anxiety, tics and learning difﬁculties).
3. Day proﬁle of ADHD symptoms (DAYAS) [4].
DAYAS assesses the daily proﬁle of ADHD and other
externalising symptoms from early morning until
bedtime. A teacher version of the questionnaire
(DAYAS-T) considers the ﬁrst and second part of
the morning at school. This complements the parent
version (DAYAS-P), which covers the remaining four
daily periods: early morning (before school), early
afternoon until 4.00 pm, late afternoon until 7.00 pm
and evening. The rating scale evaluates six items: (1)
hyperactivity, (2) inattention, (3) impulsivity, (4)
oppositional behaviour, (5) aggressive behaviour and
temper tantrums and (6) a global rating of problem
behaviour. A subscale, ADHD symptoms, comprises
items 1–3, and items 4 and 5 are combined into a
second subscale, oppositional deﬁant disorder (ODD)
symptoms. For each period, parents and teachers rate
each item on a four-point scale using the following
values: 0 = not at all; 1 = just a little; 2 = pretty
much; 3 = very much.
4. Kinder Lebensqualita ¨tsfragebogen (KINDL). A ques-
tionnaire for the assessment of health-related QoL [16].
This is a short, validated tool comprising 24 items, with
sixsubscales(physicalwell-being,emotionalwell-being,
self-esteem, family, friends and school). Three different
versions wereusedaccording toage group:KID-KINDL
(children aged 6–11 years old), the self-reported KID-
DO-KINDL (adolescents aged 12–17 years old) and
KINDL for parents of patients aged 6–17 years old.
Details about these instruments, as well as their use and
results in the OBSEER study, are described elsewhere in
this supplement [4, 8, 19].
Statistical analysis
As described above, the study sample was divided based on
previous medication into four subgroups (treatment naı ¨ve,
MPH-IR o.d., MPH-IR [o.d. and alternative MPH-MR
formulation). Post hoc multivariate analyses of variance
(MANOVA) were conducted with the four groups as
between-subject factor, and with the repeated assessment at
Visits 1, 2 and 3 as within-subject factor. Effect sizes [14,
18] were calculated post hoc as indicators of symptom
change using Cohen’s d [7] for dependent samples, by
dividing the difference between the means of Visit 1 and
Visit 3 with a variable including the pooled standard
deviations (SD) for Visits 1 and 3, and the bivariate cor-
relation (r) between the two visits, as follows:
d ¼
MeanVisit1   MeanVisit3 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðSDVisit1Þ
2 þð SDVisit3Þ
2   2   rVisit1; Visit3   SDVisit1   SDVisit3
q
Results
Patient characteristics
This analysis included 782 of the 852 patients enrolled in
the OBSEER study; children for whom the information
regarding previous therapy was unclear were not consid-
ered, and those treated previously with medications other
than MPH were also excluded due to the reduced group
size. Baseline characteristics stratiﬁed by previous MPH
treatment, ADHD diagnosis and daily MPH dosage are
presented in Table 1. Statistically signiﬁcant differences
between previous medication subgroups were found for age
(MANOVA: F(3, 764) = 3.28; P = 0.020), with older
children in the MPH-IR [o.d. and MPH-MR subgroups.
Between the three subgroups treated previously with MPH,
daily MPH dosage also varied signiﬁcantly (MANOVA:
F(2, 521) = 64.52; P\0.001), being highest in the MPH-
MR group, followed by the MPH-IR[o.d. group.
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Physician (ADHD-CGI-S), parent and teacher ratings
(FBB-ADHD) of ADHD symptoms at each study visit
stratiﬁed by prior treatment, MANOVA results (group
effect and group-by-time interaction effect) and effect
sizes (Cohen’s d) are shown in Table 2. For the
FBB-ADHD scale, the subscales inattention and hyper-
activity/impulsivity gave similar results and are, there-
fore, presented combined as total symptom score, along
with the functional impairment and attentive, reﬂexive
and enduring behaviour (attention–reﬂexivity subscale)
scores.
The main effect of time was highly signiﬁcant on all
outcome measures (data not shown), indicating signiﬁcant
symptom improvement across the three assessment points.
Signiﬁcant between-group effects were also observed on
most variables, and group-by-time interactions were sig-
niﬁcant for all outcomes analysed, indicating different
effects for different previous medications (Table 2).
Reductions in ADHD symptoms during treatment with
Equasym XL
 (from Visit 1 to Visit 3) as assessed by
clinicians on the ADHD-CGI-S scale are shown as effect
sizes (Cohen’s d) in Fig. 1a. The largest reduction was
observed in the treatment-naı ¨ve subgroup (d = 1.73), fol-
lowed in order of decreasing reduction by MPH-IR o.d.,
MPH-IR[ o.d. and MPH-MR (d = 0.76). Although the
effect sizes for FBB-ADHD parameters were somewhat
smaller (Fig. 1b), the same proﬁle was observed for parent
and teacher ratings (FBB-ADHD total score), with the
largest changes being found in the subgroup without prior
medication. For teacher ratings, effect sizes in the sub-
groups with previous medication were smaller than for
parent ratings.
Parent and teacher ratings of ADHD and ODD symp-
toms (DAYAS-P and DAYAS-T total scores) at each study
visit during different periods of the day, with the corre-
sponding MANOVA results and effect sizes, are shown in
Table 3; separate analyses for the DAYAS ADHD and
ODD symptoms subscales gave similar results (data not
shown). Signiﬁcant group-by-time interactions were
observed for all parts of the day, except the evening
(DAYAS-P), when no signiﬁcant differences between
subgroups were found. Figure 2 illustrates the reductions in
ADHD and ODD symptoms during treatment with Equ-
asym XL
 (effect sizes) on the DAYAS-P and DAYAS-T
scales. For parent ratings, the largest reductions in ADHD
and ODD symptoms between Visit 1 and Visit 3 were
observed in the early and late afternoon for all subgroups,
except MPH-MR, while changes in the morning and
evening were generally smaller. The most marked differ-
ences between groups were also found during the early and
late afternoon, with symptom reduction most pronounced
in the subgroup with no previous medication. For teacher
ratings, the subgroup without previous medication showed
substantial improvements in ADHD and ODD symptoms
both in the ﬁrst and second half of the school morning.
Changes were moderate in the MPH-IR subgroups and
smaller in the MPH-MR subgroup, in particular during the
ﬁrst half of the morning.
Quality of life
Parent (KINDL) and patient (KID-KINDL, 6–11 years old)
ratings of QoL stratiﬁed by previous medication, with main
effects of group and group-by-time interactions (MANO-
VA) and effect sizes (Cohen’s d), are reported in Table 4.
Ratings by patients aged 12–17 years on the KIDDO-
KINDL scale were not considered because subgroups in
this age range were too small for this type of analysis. The
main effects of time were highly signiﬁcant for all outcome
parameters (data not shown). For parent-rated QoL
(KINDL), signiﬁcant group-by-time interactions were
found for the total score and the subscales self-esteem,
friends and school, but not for physical well-being, emo-
tional well-being and family. Effect sizes for the total score
Table 1 Baseline patient
characteristics stratiﬁed by
previous medication
ICD International Classiﬁcation
of Diseases [25], IR immediate
release, MPH methylphenidate,
MR modiﬁed release, o.d. once
daily, SD standard deviation
a Prior to treatment with
Equasym XL

Previous treatment (N = 782)
None
(n = 208)
MPH-IR o.d.
(n = 101)
MPH-IR[o.d.
(n = 270)
MPH-MR
(n = 203)
Baseline demographics
Males, % 80.3 79.2 80.4 82.2
Age, years (mean [SD]) 9.76 (2.74) 9.78 (2.25) 9.94 (2.40) 10.46 (2.29)
ADHD diagnosis (ICD code), %
F90.0: disturbance of activity/attention 48.1 46.5 56.3 57.1
F90.1: hyperkinetic conduct disorder 33.2 31.7 34.8 35.0
F90.8: other hyperkinetic disorders 11.1 10.9 6.7 4.9
Daily MPH dosage at Visit 1
a,
mg (mean [SD])
– 14.13 (7.48) 23.99 (10.88) 29.15 (11.28)
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123were in the moderate-to-large (C0.5) range, with largest
changes in the treatment-naı ¨ve and MPH-IR o.d. sub-
groups. Effect sizes for MPH-IR[o.d. and MPH-MR were
smaller and very similar. In patient-rated QoL (KID-
KINDL), signiﬁcant group-by-time interactions were found
for the total score and the subscales self-esteem, family,
friends and school, but not for physical well-being and
emotional well-being. Effect sizes for the total score varied
from small to large, with most pronounced changes in the
treatment-naı ¨ve subgroup. Effect sizes for the other sub-
groups were smaller and very similar.
Figure 3a illustrates the improvements in parent-rated
QoL (KINDL) by subgroup from Visit 1 to Visit 3 (effect
sizes) on the three subscales that showed signiﬁcant
group-by-time interactions (self-esteem, friends and
school).
Table 2 ADHD symptoms rated by physicians, parents and teachers stratiﬁed by previous medication with main group effect, group-by-time
interaction effect (MANOVA) and effect sizes (Cohen’s d)
Outcome measure Previous
treatment
n Visit 1 Visit 2 Visit 3 MANOVA
group
MANOVA
group-by-
time
interaction
Effect size
Mean (SD) Mean (SD) Mean (SD) F PFPCohen’s d
(Visit 1–Visit 3)
Clinical rating (CGI–S)
Global impression None 154 2.27 (0.57) 1.40 (0.66) 1.00 (0.63) 3.35 0.019 9.81 0.000 1.73
MPH-IR o.d. 77 2.10 (0.66) 1.38 (0.67) 0.96 (0.75) 1.29
MPH-IR[o.d. 213 1.88 (0.70) 1.26 (0.73) 1.02 (0.61) 1.11
MPH-MR 164 1.88 (0.64) 1.36 (0.69) 1.24 (0.65) 0.76
Parent rating (FBB-ADHD)
Total score None 185 1.81 (0.62) 1.16 (0.61) 0.95 (0.55) 3.66 0.012 9.97 0.000 1.41
MPH-IR o.d. 86 1.73 (0.61) 1.19 (0.60) 1.07 (0.61) 1.15
MPH-IR[o.d. 234 1.49 (0.63) 1.06 (0.55) 0.98 (0.52) 0.85
MPH-MR 165 1.54 (0.57) 1.25 (0.58) 1.11 (0.58) 0.79
Functional impairment None 185 2.06 (0.65) 1.34 (0.69) 1.04 (0.64) 8.28 0.000 11.19 0.000 1.36
MPH-IR o.d. 86 1.87 (0.73) 1.39 (0.69) 1.24 (0.71) 0.81
MPH-IR[o.d. 233 1.65 (0.75) 1.19 (0.72) 1.05 (0.72) 0.70
MPH-MR 165 1.78 (0.72) 1.59 (0.73) 1.36 (0.73) 0.53
Attentive, reﬂexive
and enduring behaviour
None 185 0.72 (0.57) 1.16 (0.64) 1.32 (0.59) 2.93 0.033 6.32 0.000 0.93
MPH-IR o.d. 87 0.80 (0.60) 1.11 (0.60) 1.17 (0.71) 0.54
MPH-IR[o.d. 233 1.01 (0.64) 1.21 (0.66) 1.27 (0.67) 0.37
MPH-MR 165 0.91 (0.63) 1.04 (0.60) 1.10 (0.63) 0.27
Teacher rating (FBB-ADHD)
Total score None 140 1.56 (0.70) 0.98 (0.61) 0.74 (0.49) 0.66 0.579 14.16 0.000 1.38
MPH-IR o.d. 66 1.25 (0.74) 0.97 (0.62) 0.91 (0.63) 0.51
MPH-IR[o.d. 162 1.16 (0.71) 1.00 (0.63) 0.88 (0.62) 0.43
MPH-MR 124 1.20 (0.62) 1.07 (0.63) 0.99 (0.58) 0.41
Functional impairment None 141 1.82 (0.82) 1.21 (0.77) 0.86 (0.65) 2.82 0.039 11.22 0.000 1.17
MPH-IR o.d. 65 1.45 (0.89) 1.12 (0.77) 1.03 (0.79) 0.49
MPH-IR[o.d. 160 1.25 (0.88) 1.06 (0.82) 0.93 (0.82) 0.40
MPH-MR 125 1.42 (0.85) 1.28 (0.84) 1.12 (0.74) 0.42
Attentive, reﬂexive and
enduring behaviour
None 139 0.80 (0.54) 1.15 (0.61) 1.32 (0.64) 0.75 0.523 6.46 0.000 0.78
MPH-IR o.d. 66 0.99 (0.68) 1.12 (0.71) 1.21 (0.70) 0.33
MPH-IR[o.d. 158 1.09 (0.65) 1.22 (0.64) 1.25 (0.62) 0.29
MPH-MR 121 1.08 (0.62) 1.14 (0.64) 1.18 (0.62) 0.20
CGI–S Clinical Global Impression-Severity (ADHD core symptoms and associated problems), FBB-ADHD Fremdbeurteilungsbogen fu ¨r Auf-
merksamkeitsdeﬁzit-Hyperaktivita ¨tssto ¨rung, IR immediate release, MANOVA multivariate analysis of variance, MPH methylphenidate, MR
modiﬁed release, o.d. once daily
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for MPH-MR, which had the largest effect on friends. In all
subscales, the treatment-naı ¨ve and MPH-IR o.d. subgroups
showed the most dramatic improvements during treatment
with Equasym XL
; in the other subgroups, effect sizes
were smaller and comparable across all three subscales.
Similarly, Fig. 3b shows the improvements in patient-
rated QoL (KID-KINDL) from Visit 1 to Visit 3 for the
four subscales with signiﬁcant group-by-time interactions
(self-esteem, friends, school and family).
Again, in all subgroups, the largest effect sizes were
observed for school except for MPH-MR, which had the
largest effect on family. The treatment-naı ¨ve and MPH-IR
o.d. subgroups showed the most dramatic improvements
during treatment with Equasym XL
 in all subscales. In the
other subgroups, effect sizes were smaller and comparable
across subscales.
Discussion
The hypothesis for this post hoc analysis of the data
obtained from the OBSEER study was that the effect size
of the improvements observed with Equasym XL
,a s
assessed by rating of ADHD symptoms, ODD symptoms
and QoL, should depend on the degree of symptom control
achieved with the previous medication. Following this
hypothesis, the strongest effect of Equasym XL
 should be
observed in patients without previous medication, while
substantial but smaller effects should be observed in chil-
dren treated previously with MPH-IR o.d. Effects in the
MPH-IR [o.d. or MPH-MR subgroups should be more
moderate and somewhat lower than MPH-IR o.d.
As expected, during Equasym XL
 treatment in the
OBSEER study, the largest changes in ADHD symptoms,
ODD symptoms and QoL, were observed in the treatment-
Fig. 1 Reduction in a clinician-
rated (CGI-S) and b parent- and
teacher-rated ADHD symptoms
(FBB-ADHD total score) from
Visit 1 to Visit 3 in different
previous medication subgroups,
expressed as effect size
(Cohen’s d). CGI–S Clinical
Global Impressions–Severity,
FBB-ADHD
Fremdbeurteilungsbogen fu ¨r
Aufmerksamkeitsdeﬁzit-
Hyperaktivita ¨tssto ¨rung, IR
immediate release, MR modiﬁed
release, MPH methylphenidate,
o.d. once daily
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123naı ¨ve subgroup, followed by patients treated previously
with MPH-IR o.d., MPH-IR[o.d. and MPH-MR; this was
consistently conﬁrmed on all of the rating scales used for
ADHD symptoms here, speciﬁcally CGI-S (clinical rating),
FBB-ADHD and DAYAS (parent and teacher ratings), as
well as on the KINDL scales of self-esteem, friends and
school (parent and patient ratings) and family (patient
ratings only) for QoL.
The effect sizes for ADHD symptoms (FBB-ADHD) in
the subgroup without previous medication were approxi-
mately 1.4 for both parent and teacher ratings, which is
very close to the results obtained in a recent meta-analysis
of the efﬁcacy of short-acting MPH [23]. In this meta-
analysis, the standardised pre- to post-assessment score
change (mean weighted Cohen’s d) was 1.53 (95% conﬁ-
dence intervals [CI]: 1.23–1.82) for parent ratings and 1.83
(95% CI: 1.43–2.12) for teacher ratings. Thus, similar
changes during MPH treatment can be found in treatment-
naı ¨ve groups in both randomised controlled trials and
observational trials. Conversely, in another observational
study analysing the effectiveness of a different long-acting
MPH formulation (Medikinet
 Retard/XL) [9], the effect
size for parent-rated ADHD and ODD symptoms (DAYAS
total score) was 1.1 in the subgroup without previous
medication, which is somewhat lower than the effects
observed in the present study on the FBB-ADHD scale.
Table 3 ADHD and ODD symptoms rated by teachers and parents for different parts of the day (DAYAS total score) stratiﬁed by previous
medication with main group effect, group-by-time interaction effect (MANOVA) and effect sizes (Cohen’s d)
Outcome measure Previous treatment N Visit 1 Visit 2 Visit 3 MANOVA
group
MANOVA
group-by-
time
interaction
Effect size
Mean (SD) Mean (SD) Mean (SD) FPFPCohen’s d
(Visit 1–Visit 3)
Parent rating (DAYAS-P total score)
Morning before school None 182 1.29 (0.75) 0.95 (0.65) 0.88 (0.63) 11.15 0.000 3.45 0.002 0.60
MPH-IR o.d. 86 1.20 (0.73) 0.97 (0.66) 0.95 (0.71) 0.37
MPH-IR[o.d. 224 1.33 (0.79) 0.97 (0.71) 0.97 (0.69) 0.53
MPH-MR 163 1.54 (0.73) 1.39 (0.77) 1.23 (0.79) 0.49
Afternoon None 177 1.72 (0.70) 1.07 (0.65) 1.07 (0.65) 2.99 0.014 8.77 0.000 1.24
MPH-IR o.d. 86 1.54 (0.66) 1.15 (0.64) 1.15 (0.64) 0.75
MPH-IR[o.d. 217 1.36 (0.67) 1.01 (0.62) 1.01 (0.62) 0.67
MPH-MR 163 1.43 (0.60) 1.17 (0.61) 1.17 (0.61) 0.63
Late afternoon None 181 1.69 (0.73) 1.27 (0.67) 1.14 (0.60) 1.92 0.125 2.91 0.008 0.88
MPH-IR o.d. 87 1.61 (0.69) 1.29 (0.64) 1.21 (0.70) 0.59
MPH-IR[o.d. 226 1.54 (0.68) 1.23 (0.66) 1.17 (0.65) 0.54
MPH-MR 164 1.61 (0.59) 1.43 (0.57) 1.31 (0.64) 0.45
Evening None 179 1.38 (0.80) 1.21 (0.72) 1.10 (0.66) 6.04 0.000 0.92 0.480 0.38
MPH-IR o.d. 87 1.50 (0.75) 1.22 (0.74) 1.22 (0.77) 0.37
MPH-IR[o.d. 226 1.43 (0.72) 1.22 (0.72) 1.15 (0.72) 0.41
MPH-MR 164 1.64 (0.67) 1.49 (0.70) 1.36 (0.71) 0.44
Teacher rating (DAYAS-T total score)
Morning ﬁrst half None 140 1.31 (0.71) 0.81 (0.57) 0.59 (0.45) 1.22 0.301 10.84 0.000 0.99
MPH-IR o.d. 64 1.06 (0.75) 0.86 (0.70) 0.74 (0.68) 0.49
MPH-IR[o.d. 162 0.91 (0.74) 0.78 (0.63) 0.72 (0.63) 0.28
MPH-MR 122 0.96 (0.68) 0.93 (0.70) 0.87 (0.65) 0.14
Morning second half None 138 1.64 (0.81) 1.06 (0.66) 0.83 (0.58) 1.06 0.366 8.43 0.000 1.09
MPH-IR o.d. 61 1.27 (0.74) 1.01 (0.69) 0.94 (0.74) 0.46
MPH-IR[o.d. 153 1.29 (0.81) 1.07 (0.70) 0.96 (0.69) 0.45
MPH-MR 116 1.36 (0.78) 1.20 (0.79) 1.10 (0.74) 0.39
DAYAS-P/-T day proﬁle of ADHD symptoms—parent/teacher rating, IR immediate release, MANOVA multivariate analysis of variance, MPH
methylphenidate, MR modiﬁed release, o.d. once daily, ODD oppositional-deﬁant disorder, SD standard deviation
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123Fig. 2 Reduction in parent
(morning before school,
afternoon, late afternoon and
evening) and teacher ratings
(ﬁrst half of school morning and
second half of school morning)
of ADHD and ODD symptoms
for different parts of the day
(DAYAS total score) by
previous medication subgroup,
expressed as effect size
(Cohen’s d) from Visit 1 to Visit
3. DAYAS day proﬁle of ADHD
symptoms, IR immediate
release, MR modiﬁed release,
MPH methylphenidate, o.d.
once daily, ODD oppositional-
deﬁant disorder
Table 4 Parent (KINDL) and child (KID-KINDL) ratings of QoL stratiﬁed by previous medication with main group effect, group-by-time
interaction effect (MANOVA) and effect sizes (Cohen’s d)
Outcome measure Previous
medication
N Visit 1 Visit 3 MANOVA
group
MANOVA group-by-time
interaction
Effect size
Mean (SD) Mean (SD) FP F P Cohen’s d
(Visit 1–Visit 3)
Parent rating of QoL (KINDL)
Total score None 158 61.41 (13.82) 72.34 (11.25) 2.51 0.580 5.13 0.027 0.90
MPH-IR o.d. 74 60.61 (12.92) 70.62 (12.53) 0.74
MPH-IR[o.d. 197 65.40 (13.32) 72.15 (11.39) 0.56
MPH-MR 136 62.90 (11.93) 69.24 (11.50) 0.53
Physical well-being None 163 72.84 (18.54) 78.83 (16.62) 0.16 0.921 0.34 0.794 0.33
MPH-IR o.d. 74 71.28 (15.99) 78.21 (18.22) 0.38
MPH-IR[o.d. 201 72.08 (18.83) 79.48 (14.09) 0.42
MPH-MR 137 71.03 (17.30) 79.09 (17.01) 0.42
Emotional well-being None 163 67.73 (17.34) 75.61 (14.32) 1.05 0.371 0.85 0.467 0.46
MPH-IR o.d. 74 65.03 (17.58) 73.73 (16.16) 0.50
MPH-IR[o.d. 201 69.68 (17.48) 75.28 (15.50) 0.31
MPH-MR 137 67.43 (16.72) 74.18 (14.48) 0.45
Self-esteem None 163 53.09 (19.59) 65.50 (15.81) 4.00 0.008 5.39 0.001 0.66
MPH-IR o.d. 74 51.41 (18.00) 62.33 (16.32) 0.60
MPH-IR[o.d. 201 58.71 (17.64) 65.53 (16.31) 0.39
MPH-MR 137 54.87 (16.63) 59.87 (15.39) 0.29
Family None 163 60.20 (20.46) 69.93 (16.54) 2.43 0.065 2.15 0.930 0.56
MPH-IR o.d. 74 59.68 (20.03) 68.22 (18.66) 0.46
MPH-IR[o.d. 201 65.05 (19.14) 71.57 (16.62) 0.37
MPH SR 137 62.01 (17.87) 66.94 (16.50) 0.29
Friends None 163 59.83 (20.61) 70.64 (16.79) 0.95 0.416 3.82 0.010 0.63
MPH-IR o.d. 74 57.15 (19.48) 69.34 (16.62) 0.57
MPH-IR[o.d. 201 63.36 (20.65) 68.81 (18.78) 0.31
MPH-MR 137 59.49 (21.07) 67.29 (17.60) 0.42
S284 Eur Child Adolesc Psychiatry (2011) 20 (Suppl 2):S277–S288
123However, in the present study, slightly lower effects were
also found on the DAYAS scale at different periods
throughout the day, with the highest effect size (1.24) in the
afternoon.
It is interesting to note that on the FBB-ADHD scale,
effect sizes in the subgroups with previous medication
were smaller in teacher ratings than in parent ratings; this
may be due to the fact that in Germany, teachers observed
the children only in the morning, when the differences
between short- and long-acting medication regimens may
be less apparent and, consequently, possibly less percep-
tible to them than they were to parents. In fact, as shown by
its pharmacokinetic proﬁle, Equasym XL
 is characterised
by consistent MPH plasma concentrations and therefore
has a consistent effect for over 8 h after administration
[24]; thus, differences relative to short-acting medications
would be expected, especially in the afternoon. This is
supported by the results obtained on the DAYAS scale,
where the strongest symptom reduction compared with
previous medication was observed in the afternoon (parent
Table 4 continued
Outcome measure Previous
medication
N Visit 1 Visit 3 MANOVA
group
MANOVA group-by-time
interaction
Effect size
Mean (SD) Mean (SD) FP F P Cohen’s d
(Visit 1–Visit 3)
School None 158 56.34 (19.69) 73.62 (16.01) 3.19 0.023 10.95 0.000 0.87
MPH-IR o.d. 74 59.12 (18.51) 71.90 (15.58) 0.67
MPH-IR[o.d. 197 64.73 (17.38) 73.28 (15.57) 0.49
MPH-MR 136 61.93 (16.42) 68.01 (17.05) 0.36
Patient rating of QoL (KID-KINDL)
Total score None 120 64.00 (12.76) 74.56 (10.04) 0.49 0.690 4.87 0.002 0.91
MPH-IR o.d. 60 68.37 (12.91) 72.97 (12.17) 0.33
MPH-IR[o.d. 157 67.00 (14.13) 73.84 (12.30) 0.48
MPH-MR 83 67.20 (12.25) 71.27 (11.87) 0.31
Physical well-being None 121 75.29 (18.17) 80.73 (15.47) 1.05 0.370 0.85 0.468 0.33
MPH-IR o.d. 62 71.51 (14.92) 77.52 (15.45) 0.33
MPH-IR[o.d. 158 73.60 (18.01) 79.51 (16.13) 0.30
MPH-MR 85 74.39 (16.22) 76.59 (17.35) 0.11
Emotional well-being None 121 70.14 (16.37) 77.01 (13.72) 1.07 0.362 0.85 0.470 0.41
MPH-IR o.d. 62 70.60 (16.43) 76.41 (14.20) 0.32
MPH-IR[o.d. 158 73.37 (17.32) 78.24 (15.08) 0.27
MPH-MR 85 71.84 (16.47) 74.78 (15.92) 0.16
Self-esteem None 121 53.87 (20.16) 66.77 (17.86) 0.76 0.520 4.40 0.005 0.66
MPH-IR o.d. 62 61.26 (18.99) 64.58 (21.04) 0.15
MPH-IR[o.d. 158 58.95 (21.11) 67.29 (20.89) 0.35
MPH-MR 85 59.63 (18.02) 62.94 (19.52) 0.17
Family None 121 64.57 (19.46) 75.03 (15.21) 1.03 0.378 3.14 0.025 0.64
MPH-IR o.d. 62 72.78 (18.67) 74.29 (17.20) 0.09
MPH-IR[o.d. 158 68.95 (20.43) 75.59 (16.39) 0.33
MPH-MR 84 66.99 (19.76) 74.85 (16.12) 0.37
Friends None 121 64.72 (20.29) 74.09 (17.72) 0.14 0.937 2.20 0.088 0.53
MPH-IR o.d. 61 68.03 (20.89) 74.25 (21.17) 0.26
MPH-IR[o.d. 158 67.38 (22.90) 72.46 (20.14) 0.24
MPH–MR 85 69.12 (20.12) 71.32 (17.18) 0.11
School None 120 54.27 (22.47) 72.41 (16.10) 0.46 0.711 6.46 0.000 0.82
MPH-IR o.d. 61 62.77 (21.53) 68.95 (18.92) 0.29
MPH-IR[o.d. 157 60.20 (21.73) 70.08 (18.53) 0.43
MPH-MR 84 62.15 (19.37) 68.63 (18.70) 0.30
IR immediate release, KINDL Kinder Lebensqualita ¨tsfragebogen, MANOVA multivariate analysis of variance, MPH methylphenidate, MR
modiﬁed release, o.d. once daily, QoL quality of life, SD standard deviation
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123ratings), followed by the morning during school (teacher
ratings). The effects in the evening were smaller because
the effects of all medications usually diminish and wear off
in this part of the day.
To our knowledge, this is the ﬁrst observational study
assessing the differential effects of prior medication status
on patient QoL in both parent and patient ratings. The
results show differential improvements after switching to
Equasym XL
 in several of the QoL domains that are most
affected in children with ADHD: self-esteem, friends and
school (parent and patient ratings) and family (patient
ratings only). The effect sizes for these QoL domains in the
treatment-naı ¨ve group were about half of those obtained for
symptom control (FBB-ADHD); however, they were still
in the moderate-to-large range. The effects in the
subgroups with previous treatment were smaller but mostly
still substantial (C0.30).
The main limitation of this analysis is that, being based
on data from an observational study, there was no ran-
domisation, and the subgroups examined were natural
groups with different prior treatments. Therefore, it should
be taken into account that factors other than previous
medication itself may have contributed to the differences
observed. Selection bias may also have had an effect on the
results of this study, as patients were selected and switched
to Equasym XL
 only if the efﬁcacy of the previous
medication was insufﬁcient, while children for whom
treatment with other MPH formulations was successful
were not included. It should be considered, however, that
compared with randomised clinical trials, the information
Fig. 3 Improvement in QoL
from Visit 1 to Visit 3 according
to a parent (KINDL) and
b patient (KID-KINDL) ratings
(subscales with signiﬁcant
group-by-time interactions
only) by previous medication
subgroup, expressed as effect
size (Cohen’s d). KINDL Kinder
Lebensqualita ¨tsfragebogen, IR
immediate release, MR modiﬁed
release, MPH methylphenidate,
o.d. once daily, QoL quality of
life
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123gained from observational studies reﬂects real-life situa-
tions, and therefore are more directly applicable and
extendable to daily clinical practice.
In summary, the effects of Equasym XL
 were greatest
for treatment-naı ¨ve patients and similar to those found in
randomised clinical trials. However, improvements in
ADHD symptoms, ODD symptoms and QoL were also
observed in subgroups with prior treatment. This suggests
that switching to Equasym XL
 may be beneﬁcial even in
patients who only achieve suboptimal effects with a dif-
ferent stimulant medication, leading to improved symptom
control and QoL, and reduced functional impairment.
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